Rhythm Pharmaceuticals (RYTM) Price & Analysis

Compare

548 Followers

RYTM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$45.91 - $106.52

Previous CloseN/A

Volume91.33K

Average Volume (3M)625.42K

Market Cap

$6.64B

Enterprise Value$3.99B

Total Cash (Recent Filing)$291.03M

Total Debt (Recent Filing)$4.19M

Price to Earnings (P/E)―

Beta1.96

Next Earnings

Nov 11, 2025

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares Outstanding66,420,090

10 Day Avg. Volume750,284

30 Day Avg. Volume625,423

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.60

Enterprise Value/Revenue25.55

Enterprise Value/Gross Profit28.63

Enterprise Value/Ebitda-25.01

Forecast

1Y Price Target

$119.00

Price Target Upside18.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Market OpportunityThe significant global market opportunity in acquired HO is highlighted by the estimated 28,000 sufferers across the U.S., Europe, and Japan.

Product EfficacySetmelanotide has shown robust efficacy in HO patients, with a 19.8% placebo-adjusted body mass index (BMI) reduction vs. baseline and consistent impact across age-stratified subgroups.

Regulatory ApprovalThe company was recently granted Priority Review for the label expansion, indicating a meaningful market opportunity.

Bears Say

Market CompetitionPhysician panel underscores likely receptivity, indicating that current treatment options for HO are inadequate, presenting a challenge for setmelanotide to prove its effectiveness.

Sales StrategyRhythm is well-positioned to roll out setmelanotide for HO but expects to field a total of 43 territory sales managers to support the HO launch.

Rhythm Pharmaceuticals News

Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $100...

4d ago

RYTM

Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $142 from $135...

8d ago

RYTM

Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley

Morgan Stanley analyst Michael Ulz raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $122 from $109...

9d ago

RYTM

Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Rhythm Pharmaceuticals, boosting the price target to...

4d ago

RYTM

Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating

Rhythm Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from...

8d ago

RYTM

Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results

Rhythm Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from...

1M ago

RYTM

Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide

Rhythm Pharmaceuticals (RYTM) announced that the FDA has accepted for filing the company’s supplemental new drug application for...

1M ago

RYTM

Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a Phase 3...

2M ago

RYTM

Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a study titled...

2M ago

RYTM

Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a Phase 3...

2M ago

RYTM

Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a study titled...

2M ago

RYTM

3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

2M ago

WIX

Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals

Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RYTM stock, giving a Buy rating today....

2M ago

RYTM

Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $100 from $80...

2M ago

RYTM

RYTM FAQ

What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?

Rhythm Pharmaceuticals Inc lowest stock price was $45.91 and its highest was $106.52 in the past 12 months.

What is Rhythm Pharmaceuticals Inc’s market cap?

Rhythm Pharmaceuticals Inc’s market cap is $6.64B.

When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?

Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2025 which is in 39 days.

How were Rhythm Pharmaceuticals Inc’s earnings last quarter?

Rhythm Pharmaceuticals Inc released its earnings results on Aug 05, 2025. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.67 by -$0.08.

Is Rhythm Pharmaceuticals Inc overvalued?

According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rhythm Pharmaceuticals Inc pay dividends?

Rhythm Pharmaceuticals Inc does not currently pay dividends.

What is Rhythm Pharmaceuticals Inc’s EPS estimate?

Rhythm Pharmaceuticals Inc’s EPS estimate is -0.71.

How many shares outstanding does Rhythm Pharmaceuticals Inc have?

Rhythm Pharmaceuticals Inc has 66,420,090 shares outstanding.

What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?

Rhythm Pharmaceuticals Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.67. Following the earnings report the stock price went down -1.851%.

Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in RYTM

Rhythm Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-1334.54%

Trailing 12-Months

Asset Growth

-2.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders of obesity. The company operates primarily in the biotechnology sector and is committed to addressing unmet medical needs in patients suffering from these conditions. Rhythm's core product, Imcivree (setmelanotide), is specifically designed to target the underlying biological mechanisms of obesity due to certain genetic causes, enhancing patient outcomes and quality of life.

Rhythm Pharmaceuticals (RYTM) Earnings & Revenues

Historic Earnings Reports

RYTM Company Deck

RYTM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance and significant progress in international market expansion and clinical trials, particularly for setmelanotide in acquired hypothalamic obesity. However, challenges remain in the Prader-Willi Syndrome trial and rising operating expenses.View all RYTM earnings summaries

RYTM Stock 12 Month Forecast

Average Price Target

$119.00

▲(18.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","74":"$74","102":"$102","130":"$130","158":"$158"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$157.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":119,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$119.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,74,102,130,158],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.21,108.27076923076922,112.33153846153846,116.39230769230768,120.45307692307692,124.51384615384615,128.57461538461538,132.63538461538462,136.69615384615383,140.75692307692307,144.8176923076923,148.87846153846152,152.93923076923076,{"y":157,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.21,105.3476923076923,106.4853846153846,107.62307692307692,108.76076923076923,109.89846153846153,111.03615384615384,112.17384615384616,113.31153846153846,114.44923076923077,115.58692307692307,116.72461538461539,117.8623076923077,{"y":119,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,104.21,103.50153846153846,102.79307692307692,102.08461538461538,101.37615384615384,100.6676923076923,99.95923076923077,99.25076923076922,98.54230769230769,97.83384615384615,97.12538461538462,96.41692307692307,95.70846153846153,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.21,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >